Mohini Ranganathan
Overview
Explore the profile of Mohini Ranganathan including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
89
Citations
2129
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
21.
Radhakrishnan R, Ranganathan M, Skosnik P, DSouza D
Biol Psychiatry Cogn Neurosci Neuroimaging
. 2021 Jun;
6(6):600-602.
PMID: 34099185
No abstract available.
22.
Ranganathan M, Rahman M, Ganesh S, DSouza D, Skosnik P, Radhakrishnan R, et al.
World J Biol Psychiatry
. 2021 Apr;
23(1):33-45.
PMID: 33821753
Objectives: Extracellular vesicles, including exosomes, cross the blood brain barrier with their contents intact and can be assayed peripherally. Circulating exosomes have been studied in other neurodegenerative disorders, but there...
23.
Ranganathan M, DSouza D
Biol Psychiatry
. 2020 Oct;
88(9):675-677.
PMID: 33032694
No abstract available.
24.
DSouza D, Radhakrishnan R, Naganawa M, Ganesh S, Nabulsi N, Najafzadeh S, et al.
Mol Psychiatry
. 2020 Sep;
26(7):3192-3200.
PMID: 32973170
Cannabis is one of the most commonly and widely used psychoactive drugs. The rates of cannabis misuse have been increasing. Therefore, understanding the effects of cannabis use on the brain...
25.
Abdallah C, Ahn K, Averill L, Nemati S, Averill C, Fouda S, et al.
Neuropsychopharmacology
. 2020 Sep;
46(2):478-485.
PMID: 32967000
Over the past decade, various N-methyl-D-aspartate modulators have failed in clinical trials, underscoring the challenges of developing novel rapid-acting antidepressants based solely on the receptor or regional targets of ketamine....
26.
Schindler E, Schnakenberg Martin A, Sewell R, Ranganathan M, DeForest A, Pittman B, et al.
Psychopharmacology (Berl)
. 2020 Jul;
237(10):3097-3107.
PMID: 32632491
Rationale: Animal studies and anecdotal human reports suggest that cannabinoids have antinociceptive effects. Controlled human studies have produced mixed results. Objectives: We sought to reduce existing variability by investigating the...
27.
Beck K, Hindley G, Borgan F, Ginestet C, McCutcheon R, Brugger S, et al.
JAMA Netw Open
. 2020 May;
3(5):e204693.
PMID: 32437573
Importance: Ketamine hydrochloride is increasingly used to treat depression and other psychiatric disorders but can induce schizophrenia-like or psychotomimetic symptoms. Despite this risk, the consistency and magnitude of symptoms induced...
28.
Ganesh S, Cortes-Briones J, Ranganathan M, Radhakrishnan R, Skosnik P, DSouza D
Int J Neuropsychopharmacol
. 2020 May;
23(9):559-570.
PMID: 32385508
Introduction: There is increasing interest in the relationship between cannabinoids and psychosis. While individual human laboratory studies have been critical in demonstrating that cannabinoids (e.g., delta-9-tetrahydrocannabinol [THC]) can induce acute...
29.
Hu Y, Ranganathan M, Shu C, Liang X, Ganesh S, Osafo-Addo A, et al.
Sci Rep
. 2020 Feb;
10(1):3450.
PMID: 32103029
Delta-9-tetrahydrocannabinol (THC) is known to modulate immune response in peripheral blood cells. The mechanisms of THC's effects on gene expression in human immune cells remains poorly understood. Combining a within-subject...
30.
Abdallah C, Averill L, Gueorguieva R, Goktas S, Purohit P, Ranganathan M, et al.
Neuropsychopharmacology
. 2020 Feb;
45(6):990-997.
PMID: 32092760
Twenty-four hours after administration, ketamine exerts rapid and robust antidepressant effects that are thought to be mediated by activation of the mechanistic target of rapamycin complex 1 (mTORC1). To test...